Tango Therapeutics, Inc. - 8-K Filing
Tango Therapeutics announced initial Phase 1/2 trial data showing a 92% objective response rate in pancreatic cancer patients treated with vopimetostat plus daraxonrasib. The combination also demonstrated a 90% six-month progression-free survival rate and was generally well-tolerated, leading the company to plan advancing this treatment into Phase 3 development for first-line MTAP-deleted pancreatic cancer. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $TNGX